The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Reminder...
SDC-1801 - Covid-19 studies
The UKRI-funded Covid-19 research project for SDC-1801 is expected to complete on schedule with the experimental phases finishing in June and the data analysis to complete shortly thereafter. The Company will provide a further update once the relevant data are available.
As noted in the Interim Results, initial results from this research are encouraging and demonstrate that SDC-1801 reduces the levels of cytokines associated with Acute Respiratory Distress Syndrome in human lung cells infected with SARS-CoV-2.
If the completed studies are successful, the Company plans to explore the possibility for further UK government funding from the recently launched AGILE clinical development platform, which has been established to fund Phase 1 trials and fast-track the development of potentially ground-breaking Covid-19 treatments. These activities are expected to run in parallel with the broader SDC-1801 development plan.
Yes JUNE!!!! ;)
https://www.investegate.co.uk/article.aspx?id=202106110800045420B
great upward momentum, my guess is 5.5-6p before the days out, 10p next Friday ;)
GLA, rerate in progress
https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/
last updated April 21, lots to read and digest for newbies
lets hope 1801 kick arse with no tox!!!
I for one am holding on tightly to my golden tickets T2, expecting a white knuckle ride ;)
More clarification, Jak1 Tyk2 , Critical Modulators of the Antiviral Immune Response
https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjB2YzD4ozxAhWNA2MBHQdSBDoQFjABegQIBBAD&url=https%3A%2F%2Fwww.mdpi.com%2F1999-4915%2F13%2F6%2F1102%2Fpdf&usg=AOvVaw3ciNdrR_s4YLAn2yKB1BKJ
and we wait patiently, GLALTH's
Or maybe one or more of the Agile Funders getting in ..
https://www.agiletrial.net/
https://health.economictimes.indiatimes.com/news/diagnostics/genetic-variants-linked-to-severe-covid-19-study/79694151
From December, its TYK2....
Sareum's time is near, GLALTH's
there only seems to be 1 press release on Agile on 12th Jan 2021 for 2 new potential therapies?
VIR Bio and GSK..
https://www.agiletrial.net/for-press-2/
considering it was set up in July 2020, we're looking very promising to be on their next press release, got everything crossed for the next few week
GLALTH's
Deeeeep pockets will be reading Edison...
Eagerly waiting for the preclinical results, WHO takes it forward is anyone's guess at this stage, but there will sure be a frenzy for the shares
Refresh from May 4th
https://www.edisongroup.com/publication/treading-the-tyk2-trail/29435
COVID-19 optionality just adds value
I'm holding till its signed sealed and delivered ;)
Interesting read, JAK inhibitors mentioned...
It is essential to recognize that
it is not the virus that is killing the patient, rather it is the patient’s overactive immune system.
[367,370,403,461] The flames of the “cytokine fire” are out of control and need to be extinguished.
Providing supportive care (with ventilators that themselves stoke the fire) and waiting for the cytokine
fire to burn itself out simply does not work… this approach has FAILED and has led to the death of tens
of thousands of patients.
https://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwjLusCZ4ufwAhVk0uAKHWg-D6EQFjACegQIBBAD&url=https%3A%2F%2Fcovid19criticalcare.com%2Fwp-content%2Fuploads%2F2020%2F12%2FFLCCC-Protocols-%25E2%2580%2593-A-Guide-to-the-Management-of-COVID-19.pdf&usg=AOvVaw2zJhEj1HqGQ_KitERDPlBQ
Then comes along SDC1801 to put out the fire, fingers crossed. My tickets are well and truly staying put till the news drops.
GLA , not long to go ...